

**HER2-SPECIFIC HIGHLY SCALABLE CAR NK CELL (ANTI-HER2-CAR SNK02) EXHIBITS A SIGNIFICANTLY ENHANCED ANTITUMOR ACTIVITY AGAINST HER2-EXPRESSING TUMORS AS AN OFF-THE-SHELF ALLOGENEIC IMMUNE CELL THERAPY**

<sup>1</sup>Yong-hee Rhee\*, <sup>1</sup>Hee-Sung Chae, <sup>1</sup>Minji Kim, <sup>1</sup>Seo-Gu Kang, <sup>1</sup>Joungmin Lee, <sup>2</sup>Yoon Mi Kang, <sup>1</sup>Jae Seob Jung, <sup>2</sup>Paul Y Song, <sup>2,1</sup>Yong Man Kim, <sup>1</sup>Minchan Gil. <sup>1</sup>NKMAX Co., Ltd., Seongnam, Gyeonggi-do, Republic of Korea; <sup>2</sup>NKGenbiotech, Inc., Santa Ana, CA, USA

**Background** Although anti-HER2 monoclonal antibodies (e.g., trastuzumab) are currently recognized as effective therapeutics in patients with HER2-overexpressing tumors, a significant number of patients demonstrate resistance to this treatment. Genetic modification of NK cells to express a HER2-specific chimeric antigen receptor (CAR) is likely a better therapeutic approach against HER2-positive solid tumors. SNK02 is a highly scalable, off-the-shelf allogeneic NK cell product in clinical development with high purity, cytotoxicity, and tumor site migration potential. In this study, we aimed to develop allogeneic anti-HER2-CAR NK cells (CAR-SNK02) using the SNK02 manufacturing platform and to test their antitumor activity against HER2-expressing cancers.

**Methods** The CAR-SNK02 cells were generated by *ex vivo* feeder-stimulated expansion of peripheral blood NK cells along with transduction of retrovirus expressing anti-HER2 CAR and membrane-bound IL-15 using the SNK02 manufacturing platform. The CAR-SNK02 cells were characterized for their CAR expression, cytotoxicity, degranulation, and cytokine production in response to ER2-positive cancer cells. The stability of CAR expression and cytotoxicity were also examined after freezing and thawing.

**Results** The CAR-SNK02 cells underwent a billion-fold expansion over a 45–46 day culture period, through feeder cell and cytokine stimulation, while maintaining persistent high expression of the CAR in over 80% of the cells during expansion. Upon target cell stimulation, the expanded CAR-SNK02 cells exhibited potent anti-cancer activity against HER2-positive cancer cells, as well as increased cytokine production and high levels of degranulation. Moreover, the CAR-SNK02 cells maintained key phenotypic features of NK cells, including high expression of NK cell activating and chemokine receptors without signs of exhaustion, indicating their preserved functionality. The CAR-SNK02 cells showed enhanced survival under IL-2-deprived conditions, confirming activity of IL-15. Furthermore, the NK cells maintained CAR expression and enhanced cytotoxicity against HE2-expressing cancer cells even after freezing and thawing. Importantly, they effectively eliminated cancer cells with low HER2 expression levels, surpassing limitations of trastuzumab-induced antibody-dependent cellular cytotoxicity (ADCC) of NK cells.

**Conclusions** High expandability of the CAR-SNK02 cells, coupled with their enhanced antitumor activity against HER2-expressing cancer cells, even after freezing and thawing, highlights their promising potential as an off-the-shelf immune cell therapy. In addition, the SNK02 platform serves as a valuable foundation for further exploration and advancement of genetically engineered NK cell therapies. We are currently testing the antitumor activity of the CAR-SNK02 cells in a xenograft mouse model of cancer expressing HER2 for future translation into human trials.

**Ethics Approval** This study was approved by the Institutional Review Board (IRB) approval of Asan Medical Center (IRB No. 2021–0354).

<http://dx.doi.org/10.1136/jitc-2023-SITC2023.0296>